Physician profile
Victor D Turow
NPI 1942349485
$2,952.88
in general payments reported to CMS, 2019-2025
23 companies · $661 in 2025
The $661 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $269 · 2021: $311 · 2022: $461 · 2023: $463 · 2024: $500 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,623.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $485.78 | 2019-2025 | |
| Kaleo, INC. | $266.18 | 2019-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $219.06 | 2025 | Neffy |
| Corium, LLC | $213.66 | 2022-2024 | Azstarys |
| Aytu Biopharma, INC. | $206.29 | 2019-2023 | |
| Cranial Technologies, INC | $187.11 | 2021-2025 | Doc Band |
| Sanofi Pasteur INC. | $184.42 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $178.72 | 2020-2025 | Vaxelis, Vaxneuvance, Gardasil |
| Kowa Pharmaceuticals America, INC. | $164.60 | 2024-2025 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $155.26 | 2020-2022 | |
| Glaxosmithkline, LLC. | $127.76 | 2019-2023 | Bexsero, Pediarix, Rotarix |
| Phadia US INC. | $94.14 | 2019-2024 | Immunocap |
| Sobi, INC | $88.20 | 2019-2023 | |
| Vertical Pharmaceuticals, LLC | $78.47 | 2025 | Relexxii |
| Seqirus USA INC | $63.85 | 2023-2025 | Flucelvax Quadrivalent, Flucelvax |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $57.01 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $48.68 | 2021-2024 | Flumist Quadrivalent |
| Shire North American Group INC | $37.40 | 2019 | |
| Ironshore Pharmaceuticals INC. | $22.06 | 2020 | |
| Genentech USA, INC. | $21.87 | 2019 | |
| Galderma Laboratories, L.P. | $18.87 | 2021 | |
| Neos Therapeutics, LP | $17.00 | 2024 | Adzenys Xr-Odt |
| Incyte Corporation | $16.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Turow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.